CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,663 shares at an average $21.02 ($140,073)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $22.33 ($279,155)
- 4 Planned sale PRESIDENT AND CEO sold 12,500 shares at $21.82 ($272,739)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K/A Event Results of operations
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at an average $17.40 ($116,034)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at $22.08 ($276,025)
- 4 Planned sale PRESIDENT AND CEO sold 12,500 shares at $21.33 ($266,654)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at $20.10 ($133,993)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $20.40 ($66,291)
Page 7 of 40 · 798 filings